Amylyx Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Amylyx Pharmaceuticalshan disminuido a un ritmo medio anual de -22.3%, mientras que en la industria Pharmaceuticals los ingresos han sido de growing a 8.5% anuales. Los ingresos han sido growing a un ritmo medio de 151.3% al año. Amylyx Pharmaceuticals La rentabilidad de los fondos propios de la empresa es de 0.4% y sus márgenes netos son de 0.6%.

Información clave

-3.6%

Tasa de crecimiento de los beneficios

37.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	6.0%
Tasa de crecimiento de los ingresos	135.1%
Rentabilidad financiera	11.4%
Margen neto	12.9%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates

Jul 18

Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis

Jul 04

Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last

Jun 17

We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

May 07

Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy

Mar 29

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Amylyx Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:AMLX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	381	49	188	0
30 Sep 23	294	2	177	10
30 Jun 23	192	-73	158	0
31 Mar 23	94	-149	145	2
31 Dec 22	22	-198	127	0
30 Sep 22	0	-184	101	67
30 Jun 22	0	-153	82	0
31 Mar 22	0	-121	59	20
31 Dec 21	0	-88	39	0
30 Sep 21	1	-68	28	0
31 Dec 20	1	-42	15	0
31 Dec 19	1	-14	3	0

Ingresos de calidad: AMLX tiene un gran one-off gain de $9.9M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: AMLX fueron rentables en el pasado.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AMLX se ha vuelto rentable en los últimos 5 años, con un crecimiento de los beneficios de -22.3% al año.

Acelerando crecimiento: AMLX ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su media de 5 años.

Beneficios vs. Industria: AMLX ha pasado a ser rentable en el último año, lo que hace difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (-17.3%).

Rentabilidad financiera

Alto ROE: El Retorno sobre el capital de AMLX (0.4%) se considera bajo.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Amylyx Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: EPS misses analyst expectations

Amylyx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Amylyx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Amylyx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Amylyx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Amylyx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Recent updates

Investor sentiment deteriorates as stock falls 20%

Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Consensus revenue estimates fall by 45%

Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market

New major risk - Revenue and earnings growth

Amylyx Pharmaceuticals, Inc. Appoints Bernhardt Zeiher to Its Board of Directors

Investor sentiment deteriorates as stock falls 83%

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Rosen Law Firm Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Consensus revenue estimates fall by 19%

An ALS Drug Fails Again

Amylyx Pharmaceuticals, Inc. Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

Investor sentiment improves as stock rises 28%

Consensus EPS estimates fall by 54%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Amylyx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc

Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 Orion Study of Amx0035 in Progressive Supranuclear Palsy (Psp)

Amylyx Pharmaceuticals, Inc. Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

Amylyx Pharmaceuticals Appoints Camille L. Bedrosian as Chief Medical Officer

Price target decreased by 17% to US$39.40

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

New minor risk - Share price stability

Amylyx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium

Amylyx Pharmaceuticals, Inc. Receives Negative Chmp Opinion on Its Marketing Authorisation Application for Amx0035 for the Treatment of Als in the European Union Following Re-Examination Process

Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing Centaur to Historical Clinical Trial Control

Amylyx Pharmaceuticals Provides Update on Acces Compassionnel for AMX0035 in France

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Amylyx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Quebec for the Public Reimbursement of Albriza

Amylyx Pharmaceuticals Canada Enters into Product Listing Agreement with Ontario for Public Reimbursement of ALBRIOZA Through Ontario Drug Benefit Program

Amylyx Pharmaceuticals, Inc. Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

Amylyx Pharmaceuticals, Inc. Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union

Insider notifies of intention to sell stock

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Forecast breakeven date moved forward to 2023

Co-Founder notifies of intention to sell stock

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Consensus revenue estimates increase by 41%

Amylyx Pharmaceuticals, Inc. Announces Completion of Enrollment in Global Phase 3 Phoenix Trial of AMX0035 in ALS

Co-Founder notifies of intention to sell stock

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Amylyx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Amylyx Pharmaceuticals, Inc. Announces Resignation of Isaac Cheng as Board of Directors

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Consensus forecasts updated

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Consensus forecasts updated

No longer forecast to breakeven

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Amylyx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approval of RELYVRIO for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds

Amylyx Pharmaceuticals, Inc. Announces FDA Advisory Committee Supports Approval of Amx0035 for the Treatment of ALS

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Amylyx plunges 28% after FDA briefing documents on ALS drug

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Consensus forecasts updated

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Amylyx Pharmaceuticals, Inc. Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022

Desglose de ingresos y gastos
Beta